Merck KGaA (OTCMKTS:MKKGY - Get Free Report) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,600 shares, a drop of 97.2% from the November 15th total of 56,900 shares. Based on an average trading volume of 245,500 shares, the short-interest ratio is presently 0.0 days.
Analyst Upgrades and Downgrades
Separately, The Goldman Sachs Group started coverage on Merck KGaA in a research report on Thursday, September 19th. They set a "buy" rating for the company.
Get Our Latest Analysis on MKKGY
Merck KGaA Stock Performance
Shares of MKKGY traded down $0.24 during trading hours on Friday, reaching $29.51. 159,143 shares of the company's stock traded hands, compared to its average volume of 72,295. The firm has a market capitalization of $19.07 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 2.37 and a beta of 0.93. The business's fifty day simple moving average is $32.01 and its two-hundred day simple moving average is $34.48. Merck KGaA has a twelve month low of $28.96 and a twelve month high of $39.17. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.33 and a quick ratio of 0.91.
About Merck KGaA
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
